International Journal of Hematology and Oncology 2022, Vol 32, Num 3 Page(s): 123-129
Association of CD14 -159 Gene Polymorphism with Characteristics and Outcome of Diffuse Large B-cell Lymphomas


1Military Medical Academy, Clinic of Hematology, Belgrade, SERBIA
2Military Medical Academy, Institute of Medical Research, Belgrade, SERBIA

Keywords: Diffuse large B-cell lymphoma, CD14, Genotyping
The aim of this study was to assess the association between CD14 -159 genotypes and DLBCL characteristics, clinical course and outcome, respectively. The study included 114 patients with the newly diagnosed DLBCL. All patients received R-CHOP therapy (6-8 cycles). CD14 -159C→T genotyping was performed by using PCR RFLP. Obtained frequencies of CD14 -159 genotypes were as follows: 23% of CC, 41% of CT and 36% of TT. Statistically significant association between CD14 genotypes and clinical characteristics (age, sex, disease stage, extranodal sites, bulky disease, IPI, lymphocyte and lymphocyte/monocyte count) was found only for extranodal disease (p= 0.01). CT/TT carriers more frequently presented extranodal disease (OR 3.191, 95% CI: 1.282-7.94). In addition, these patients had higher pretreatment values of CRP (p= 0.078). During the therapy, -infections (p= 0.083), and earlytreatment- related complications (p= 0.079) were more commonly present in carriers of CC genotype. In patients with extranodal DLBCL, TT genotype was associated with superior OS (p= 0.049) and RFS, (p=0.018). Multivariate analysis revealed IPI (HR 2.422, 95% CI 1.114-5.264; p= 0.026) and CD14 TT genotype (HR 0.503, 95% CI: 0.262 – 0.963; p= 0.038) as the most prominent factors for OS. Our study reveals the association of CD14-159 T allele with the presence of extranodal DLBCL and elevated CRP level at diagnosis. However, during the treatment T allele manifested protective role since patients with CT/TT genotypes less frequently experienced infections and early-treatment-related complications. In addition, TT genotype was associated with improved survival, but only in patients with extranodal disease.